## Genomically defined cancers

### Avapritinib: PDGFRA
- PDGFRA GIST\(^1,2,3\)  
- [U.S., EU](#)

### Pralsetinib: RET
- RET+ NSCLC\(^1,2,4,5\)
- EGFR+ NSCLC (+osimertinib)\(^2,4\)
- RET+ MTC\(^1,2,4,6\)
- RET+ thyroid cancer\(^1,4,6\)
- Other RET-altered solid tumors\(^1,2,4\)
- [MAA](#)
- [U.S.](#)

### Fisogatinib: FGFR4
- Advanced HCC\(^3\)
- Advanced HCC (+CS1001)\(^3\)

### BLU-945: EGFR+ T790M/C797S triple mutant
- EGFR+ NSCLC\(^1\)

### Research program: EGFR+ C797S double mutant
- EGFR+ NSCLC\(^1\)

### Research programs: 2 undisclosed targets

## Rare diseases

### Avapritinib: KIT
- Advanced SM\(^2\)
- Indolent SM\(^3\)
- [NDA](#)

### BLU-263: KIT
- Indolent SM

## Cancer immunotherapy

### Research program: MAP4K1\(^7\)

### Research programs: 3 undisclosed targets\(^1\)

---

1. Unresectable or metastatic disease.
2. Cstone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan.
3. Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Received conditional marketing authorization in Europe for the treatment of adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. In collaboration with Roche. Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib in the U.S., and Roche has exclusive rights to develop and commercialize pralsetinib outside the U.S., excluding the CStone territory.
4. Received accelerated approval in the U.S. for the treatment of adults with metastatic RET fusion-positive NSCLC. Continued approval may be contingent on a confirmatory trial. The proposed indication for the MAA is locally advanced or metastatic RET fusion-positive NSCLC previously treated with platinum-based chemotherapy.
5. Received accelerated approval in the U.S. for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET-fusion positive thyroid cancer.
6. In collaboration with Roche. Blueprint Medicines has U.S. commercial rights for up to two programs. Roche has worldwide commercialization rights for up to two programs and ex-U.S. commercialization rights for up to two programs.

Not for promotional use.